Multidrug treatment with nelfinavir and cepharanthine against COVID-19

@article{Ohashi2020MultidrugTW,
  title={Multidrug treatment with nelfinavir and cepharanthine against COVID-19},
  author={Hirofumi Ohashi and Koichi Watashi and Wakana Saso and Kaho Shionoya and Shoya Iwanami and Takatsugu Hirokawa and Tsuyoshi Shirai and Shigehiko Kanaya and Yusuke Ito and Kwang Sup Kim and Kazane Nishioka and Shuji Ando and Keisuke Ejima and Yoshiki Koizumi and Tomohiro Tanaka and Shin Aoki and Kouji Kuramochi and Tadaki Suzuki and Katsumi Maenaka and Tetsuro Matano and Masamichi Muramatsu and Masayuki Saijo and Kazuyuki Aihara and Shingo Iwami and Makoto Takeda and Jane A. McKeating and Takaji Wakita},
  journal={bioRxiv},
  year={2020}
}
Antiviral treatments targeting the emerging coronavirus disease 2019 (COVID-19) are urgently required. We screened a panel of already-approved drugs in a cell culture model of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and identified two new antiviral agents: the HIV protease inhibitor Nelfinavir and the anti-inflammatory drug Cepharanthine. In silico modeling shows Nelfinavir binds the SARS-CoV-2 main protease consistent with its inhibition of viral replication, whilst… Expand
Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19
TLDR
This review critically analyzes and consolidates available evidence establishing CEP’s potential therapeutic importance as a drug of choice in managing COVID-19 cases. Expand
Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19
TLDR
This review summarizes the major repurposing approaches that have been proposed or are already being studied in clinical trials for COVID-19 and discusses means to discover repurposed drugs and the ongoing challenges associated with the off-label use of existing drugs in the context of the CO VID-19 outbreak. Expand
Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients
TLDR
A number of broad-spectrum antivirals with potential efficacy to inhibit the virus replication via targeting the virus spike protein (S protein), RNA-dependent RNA polymerase (RdRp) and papain-like protease (PLpro) have been evaluated as possible treatment options against SARS-CoV-2 in COVID-19 patients. Expand
Drug repurposing approach to fight COVID-19
TLDR
The present review will focus on the repurposing efficacy of the currently used drugs against COVID-19 and their mechanisms of action, pharmacokinetics, dosing, safety, and their future perspective. Expand
The Potential of Antiviral Peptides as COVID-19 Therapeutics
TLDR
Interestingly, there are AVPs demonstrated to exert prophylactic and therapeutic effects against coronaviruses (CoVs) and it is suggested that further development of this class of compounds in the face of the current pandemic threat is warranted. Expand
A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19)
TLDR
This review summarizes the epidemiological characteristics, pathogenesis, virus structure and targeting strategies of COVID-19, and focuses on the re-purposing of clinically approved drugs and Chinese herbal medicines that may be used to treat CO VID-19 and provide new ideas for the discovery of small molecular compounds with potential therapeutic effects on novel COVID -19. Expand
Targeting Proteases for Treating COVID-19
TLDR
How host and viral proteases participated in the pathogenesis of COVID-19 as well as the prospects and ongoing clinical trials of protease inhibitors as treatments are discussed. Expand
Recent progress in the repurposing of drugs/molecules for the management of COVID-19
TLDR
FDA approved broad-spectrum drugs/molecules could be repurposed against the COVID-19 and are under clinical trials, if the outcome of these trials proves positive, it could be used to manage CO VID-19 pandemic. Expand
Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches
  • K. Watashi
  • Medicine
  • Biochemical and Biophysical Research Communications
  • 2020
TLDR
This article summarizes the studies using in silico and in vitro approaches to identify therapeutic candidates among approved drugs that target the SARS-CoV-2 life cycle. Expand
Transcriptome analysis of cepharanthine against a SARS-CoV-2-related coronavirus
TLDR
Evidence for CEP as a promising therapeutic option for SARS-CoV-2 infection is provided, with RNA-sequencing results showing the virus perturbed the expression of multiple genes including those associated with cellular stress responses such as endoplasmic reticulum stress and heat shock factor 1 (HSF1)-mediated heat shock response. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus
TLDR
Nelfinavir strongly inhibited replication of the SARS coronavirus (SARS-CoV) and has potential as a good lead compound for designing anti-SARS drugs. Expand
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
TLDR
In vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients are evaluated. Expand
A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection.
TLDR
Study of viral genotype and phenotype after virus rebound revealed that the initial active site mutation allowing for nelfinavir resistance is mediated by a unique amino acid substitution in the HIV-1 protease D30N, which does not confer in vitro phenotypic cross-resistance to the currently available protease inhibitors. Expand
Small molecules targeting severe acute respiratory syndrome human coronavirus.
TLDR
A cell-based assay was developed to screen existing drugs, natural products, and synthetic compounds to identify effective anti-SARS agents, and of particular interest are the two anti-HIV agents, one as an entry blocker and the other as a 3CL protease inhibitor. Expand
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
TLDR
This article summarizes agents with potential efficacy against SARS-CoV-2 and indicates some promising results have been achieved thus far. Expand
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
TLDR
This study evaluated the antiviral efficiency of five FAD-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine and two well-known broad-spectrum antiviral drugs remdesivir and favipiravir against a clinical isolate of 2019-nCoV in vitro. Expand
Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model
TLDR
The results strongly suggest that CEP is a wide-spectrum inhibitor of pan-betacoronavirus, and further study of CEP for treatment of 2019-nCoV infection is warranted. Expand
Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection
TLDR
This study showed how cell culture data can be combined with a mathematical model and computer simulation to quantify the anti-HCV drug efficacy of different drug concentrations and combinations in a preclinical setting, and hence develop a quantitative basis for selecting drug combinations prior to costly clinical trials. Expand
Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells
TLDR
TET, FAN, and CEP treatment dramatically suppressed the replication of HCoV-OC43 as well as inhibited viral S and N protein expression and reduced the virus-induced host response as compared with the vehicle control. Expand
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
TLDR
In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care, and future trials in patients withsevere illness may help to confirm or exclude the possibility of a treatment benefit. Expand
...
1
2
3
4
...